CGTX Cognition Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why CGTX matters now
Cognition Therapeutics, Inc. (CGTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.09 with +0.00% on the session and $80.2M in market capitalization; recent performance reads 1-month +30.63% and YTD +7.41%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-4.6M, and EPS of $-0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -19.0%.
The latest indexable market news headline is "Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Doyle John Brendan filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.32
P/S
0.00
EV/EBITDA
-3.94
DCF Value
$0.60
FCF Yield
-19.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-72.7%
ROA
-54.2%
ROIC
-141.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-4.6M | $-0.05 |
| Q4 2025 | $0.00 | $-3.3M | $-0.04 |
| FY 2025 | $0.00 | $-23.5M | $-0.32 |
| Q3 2025 | $0.00 | $-4.9M | $-0.06 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.75
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.